Join
Live feed
·
PRReleasevia Quantisnow
Genmab A/S logo

Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

ByQuantisnow·Wall Street's wire, on your screen.
GMAB· Genmab A/S
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track GMAB (Genmab A/S) and more on Quantisnow.